ONWD Stock Overview
Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Onward Medical N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.30 |
| 52 Week High | €6.58 |
| 52 Week Low | €1.85 |
| Beta | 0.80 |
| 1 Month Change | -13.68% |
| 3 Month Change | 143.12% |
| 1 Year Change | 8.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -58.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONWD | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | -7.3% | -0.8% | -0.5% |
| 1Y | 8.4% | 5.2% | -4.6% |
Return vs Industry: ONWD exceeded the Belgian Medical Equipment industry which returned 5.2% over the past year.
Return vs Market: ONWD exceeded the Belgian Market which returned -4.6% over the past year.
Price Volatility
| ONWD volatility | |
|---|---|
| ONWD Average Weekly Movement | 25.0% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.8% |
| 10% least volatile stocks in BE Market | 2.6% |
Stable Share Price: ONWD's share price has been volatile over the past 3 months.
Volatility Over Time: ONWD's weekly volatility has increased from 14% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 96 | Dave Marver | www.onwd.com |
Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia.
Onward Medical N.V. Fundamentals Summary
| ONWD fundamental statistics | |
|---|---|
| Market cap | €159.98m |
| Earnings (TTM) | -€36.06m |
| Revenue (TTM) | €2.11m |
75.7x
P/S Ratio-4.4x
P/E RatioIs ONWD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONWD income statement (TTM) | |
|---|---|
| Revenue | €2.11m |
| Cost of Revenue | €16.37m |
| Gross Profit | -€14.26m |
| Other Expenses | €21.80m |
| Earnings | -€36.06m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | -1.19 |
| Gross Margin | -674.78% |
| Net Profit Margin | -1,706.53% |
| Debt/Equity Ratio | 41.7% |
How did ONWD perform over the long term?
See historical performance and comparison